Upregulation and pathogenic roles of CCL18-CCR8 axis in IgG4-related disease

References

• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1–14.
   PubMed Web of Science ®Google Scholar
• John HS, Yoh Z, Vikram D. IgG4-related disease. N Engl J Med. 2012;366:539–51.
   PubMed Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Nojima M, Takahashi H, Yokoyama Y, Ishigami K, Yajima H, et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford). 2015;54(1):45–9.
   PubMed Web of Science ®Google Scholar
• Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–15.
   PubMed Web of Science ®Google Scholar
• Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755–62.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57–66.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Matsuo N, Iizuka M, Tsuzuki S, Kondo Y, Tanaka A, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res Ther. 2012;14(4):R171.
   PubMed Web of Science ®Google Scholar
• Umehara H, Nakajima A, Nakamura T, Kawanami T, Tanaka M, Dong L, Kawano M. IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity. Int Immunol. 2014;26(11):585–95.
   PubMed Web of Science ®Google Scholar
• Moriyama M, Tanaka A, Maehara T, Furukawa S, Nakashima H, Nakamura S. T helper subsets in Sjögren's syndrome and IgG4-related dacryoadenitis and sialoadenitis: a critical review. J Autoimmun. 2014; 51:81–8.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Nakai Y, Iizuka M, Asashima H, Hagiya C, Tsuzuki S, et al. DNA microarray analysis of labial salivary glands in IgG4-related disease: comparison with Sjögren's syndrome. Arthritis Rheumatol. 2014;66(10):2892–9.
   PubMed Web of Science ®Google Scholar
• Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005;78(1):14–26.
   PubMed Web of Science ®Google Scholar
• Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med. 2013;210(10):1889–98.
   PubMed Web of Science ®Google Scholar
• Ohta M, Moriyama M, Maehara T, Gion Y, Furukawa S, Tanaka A, et al. DNA microarray analysis of submandibular glands in IgG4-related disease indicates a role for MARCO and other innate immune-related proteins. Medicine (Baltimore). 2016;95(7):e2853.
   PubMed Web of Science ®Google Scholar
• Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol. 2002;169(5):2685–93.
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002;168(11):5885–92.
   PubMed Web of Science ®Google Scholar
• Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest. 2014;124(5):2009–22.
   PubMed Web of Science ®Google Scholar
• Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008;205(11):2643–55.
   PubMed Web of Science ®Google Scholar
• Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, et al. CCR8 + FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci USA. 2017;114(23):6086–91.
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475–87.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35–45.
   PubMed Web of Science ®Google Scholar
• Xanthou G, Polihronis M, Tzioufas AG, Paikos S, Sideras P, Moutsopoulos HM. “Lymphoid” chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum. 2001;44(2):408–18.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Clin Immunol. 2015;156(1):9–18.
   PubMed Web of Science ®Google Scholar
• Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol. 2003;29(6):743–9.
   PubMed Web of Science ®Google Scholar
• Chenivesse C, Chang Y, Azzaoui I, Ait Yahia S, Morales O, Plé C, et al. Pulmonary CCL18 recruits human regulatory T cells. J Immunol. 2012;189(1):128–37.
   PubMed Web of Science ®Google Scholar
• Chenivesse C, Tsicopoulos A. CCL18 - Beyond chemotaxis. Cytokine. 2018;109:52–6.
   PubMed Web of Science ®Google Scholar
• Chang Y, de Nadai P, Azzaoui I, Morales O, Delhem N, Vorng H, et al. The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. FASEB J. 2010;24(12):5063–72.
   PubMed Web of Science ®Google Scholar
• Azzaoui I, Yahia SA, Chang Y, Vorng H, Morales O, Fan Y, et al. CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects. Blood. 2011;118(13):3549–58.
   PubMed Web of Science ®Google Scholar
• Oshio T, Kawashima R, Kawamura YI, Hagiwara T, Mizutani N, Okada T, et al. Chemokine receptor CCR8 is required for lipopolysaccharide-triggered cytokine production in mouse peritoneal macrophages. PLoS One. 2014;9(4):e94445.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis. 2018;77(9):1386–7.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod Rheumatol. 2018;28(1):58–65.
   PubMed Web of Science ®Google Scholar